Impact of HIV infection on aging and immune status

References

• Wandeler G, Johnson LF, Egger M. Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population. Current Opinion HIV AIDS. 2016 Sep;;11(5):492–500.
   PubMed Web of Science ®Google Scholar
• Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011;62:141–155.
   PubMed Web of Science ®Google Scholar
• Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011 Dec;;53(11):1120–1126. .
   PubMed Web of Science ®Google Scholar
• Appay V, Kelleher AD. Immune activation and immune aging in HIV infection. Current Opinion HIV AIDS. 2016 Mar;11(2):242–249.
   PubMed Web of Science ®Google Scholar
• de Armas LR, Pallikkuth S, George V, et al. Reevaluation of immune activation in the era of cART and an aging HIV-infected population. JCI Insight. 2017 Oct 19 2;(20)20.
   Web of Science ®Google Scholar
• UNAIDS. Get on the fast-track, the life-cycle approach to HIV. 2016; Available at: http://www.unaids.org/sites/default/files/media_asset/Get-on-the-Fast-Track_en.pdf.
   Google Scholar
• High KP, Brennan-Ing M, Clifford DB, et al. HIV and aging: state of knowledge and areas of critical need for research. A Report to the NIH Office of AIDS Research by the HIV and Aging Working Group. Journal of Acquired Immune Deficiency Syndromes. 2012 Jul 1;60(Suppl 1):S1–18.
   Google Scholar
• Cardoso SW, Torres TS, Santini-Oliveira M, et al. Aging with HIV: a practical review. Braz J Infect Dis. 2013;17(4):464–479. . Jul-Aug;
   PubMed Web of Science ®Google Scholar
• Group ISS, Lundgren JD, Babiker AG, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015 Aug 27;373(9):795–807.
   PubMed Web of Science ®Google Scholar
• KM E, MY K. HIV and aging: reconsidering the approach to management of comorbidities. Infect Dis Clin North Am. 2019 Sep;33(3):769–786.
   PubMed Web of Science ®Google Scholar
• Kanters S, Vitoria M, Doherty M, et al. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. Lancet HIV. 2016 Nov;3(11):e510–e520. .
   PubMed Web of Science ®Google Scholar
• De Francesco D, Wit FW, Burkle A, et al. Do people living with HIV experience greater age advancement than their HIV-negative counterparts? Aids. 2019 Feb 1;33(2):259–268.
   PubMed Web of Science ®Google Scholar
• d’Arminio Monforte A, Diaz-Cuervo H, De LA, et al. Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals. Naive for Antiretrovirals (ICONA) Foundation Study Cohort in the Period 2004-2014. HIV Medicine. 2019 Feb;20(2):99–109.
   Google Scholar
• Bagkeris E, Burgess L, Mallon PW, et al. Cohort profile: the Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY) study. Int J Epidemiol. 2018 Oct 1;47(5):1391–1392e.
   PubMed Web of Science ®Google Scholar
• De Francesco D, Underwood J, Bagkeris E, et al. Risk factors and impact of patterns of co-occurring comorbidities in people living with HIV. Aids. 2019 Oct 1;33(12):1871–1880.
   PubMed Web of Science ®Google Scholar
• Schouten J, FW W, IG S, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014 Dec 15;59(12):1787–1797.
   PubMed Web of Science ®Google Scholar
• Wong C, Gange SJ, Moore RD, et al. Multimorbidity among persons living with human immunodeficiency virus in the United States. Clin Infect Dis. 2018 Apr 3 66;(8)1230–1238.
   PubMed Web of Science ®Google Scholar
• Guaraldi G, Malagoli A, Calcagno A, et al. The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65-74 years and more than 75 years. BMC Geriatr. 2018 Apr 20;18(1):99.
   PubMed Web of Science ®Google Scholar
• Smit M, Brinkman K, Geerlings S, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015 Jul;15(7):810–818. .
   PubMed Web of Science ®Google Scholar
• Nasi M, De BS, Gibellini L, et al. Ageing and inflammation in patients with HIV infection. Clin Exp Immunol. 2017 Jan;;187(1):44–52. .
   PubMed Web of Science ®Google Scholar
• Lopez-Otin C, Blasco MA, Partridge L, et al. The hallmarks of aging. Cell. 2013 Jun 6;153(6):1194–1217.
   PubMed Web of Science ®Google Scholar
• Torres RA, Aging LW. HIV/AIDS: pathogenetic role of therapeutic side effects. Lab Invest. 2014 Feb;94(2):120–128.
   PubMed Web of Science ®Google Scholar
• Leng SX, Margolick JB. Aging, sex, inflammation, frailty, and CMV and HIV infections. Cell Immunol. 2020 Feb;348:104024.
   PubMed Web of Science ®Google Scholar
• Gruver AL, Hudson LL, Sempowski GD. Immunosenescence of ageing. J Pathol. 2007 Jan;211(2):144–156.
   PubMed Web of Science ®Google Scholar
• Negredo E, Back D, Blanco JR, et al. Aging in HIV-infected subjects: a new scenario and a new view. Biomed Res Int. 2017;2017:5897298.
   PubMed Web of Science ®Google Scholar
• Tiraboschi J, Ray S, Patel K, et al. Short communication: lack of effect of maraviroc intensification on blood and gut reservoir. AIDS Res Human Retroviruses. 2017 Feb;33(2):143–146. .
   PubMed Web of Science ®Google Scholar
• van Lelyveld SF, Drylewicz J, Krikke M, et al. Maraviroc intensification of cart in patients with suboptimal immunological recovery: a 48-week, placebo-controlled randomized trial. PloS One. 2015;10(7):e0132430. .
   PubMed Web of Science ®Google Scholar
• Gandhi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLOS Med. 2010 Aug 10;7(8):8.
   Web of Science ®Google Scholar
• Hatano H, Hayes TL, Dahl V, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis. 2011 Apr 1;203(7):960–968.
   PubMed Web of Science ®Google Scholar
• Hunt PWHI. V and inflammation: mechanisms and consequences. Current HIV/AIDS Reports. 2012 Jun;9(2):139–147.
   PubMed Web of Science ®Google Scholar
• Sokoya T, Steel HC, Nieuwoudt M, et al. HIV as a cause of immune activation and immunosenescence. Mediators Inflammation. 2017;2017:6825493.
   PubMed Web of Science ®Google Scholar
• Appay V, Fastenackels S, Katlama C, et al. Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. Aids. 2011 Sep 24;25(15):1813–1822. .
   PubMed Web of Science ®Google Scholar
• Hsue PY, Hunt PW, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. Aids. 2006 Nov 28;20(18):2275–2283.
   PubMed Web of Science ®Google Scholar
• Petrara MR, Cattelan AM, Zanchetta M, et al. Epstein-Barr virus load and immune activation in human immunodeficiency virus type 1-infected patients. J Clin Virol. 2012 Mar;53(3):195–200.
   PubMed Web of Science ®Google Scholar
• Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol. 2012 Sep;10(9):655–666.
   PubMed Web of Science ®Google Scholar
• Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PloS One. 2008 Jun 25;3(6):e2516.
   PubMed Web of Science ®Google Scholar
• Massanella M, Negredo E, Puig J, et al. Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery. Aids. 2012 Nov 28;26(18):2285–2293.
   PubMed Web of Science ®Google Scholar
• Massanella M, Gomez-Mora E, Carrillo J, et al. Increased ex vivo cell death of central memory CD4 T cells in treated HIV infected individuals with unsatisfactory immune recovery. J Transl Med. 2015 Jul 17;13:230.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Pantazis N, Martin GE, et al. Exhaustion of activated CD8 T cells predicts disease progression in primary HIV-1 infection. PLoS Pathog. 2016 Jul;12(7):e1005661.
   PubMed Web of Science ®Google Scholar
• Massanella M, Fromentin R, Chomont N. Residual inflammation and viral reservoirs: alliance against an HIV cure. Current Opinion HIV AIDS. 2016 Mar;11(2):234–241.
   PubMed Web of Science ®Google Scholar
• Gomez-Mora E, Massanella M, Garcia E, et al. Elevated humoral response to cytomegalovirus in HIV-infected individuals with poor CD4+ T-cell immune recovery. PloS One. 2017;12(9):e0184433. .
   PubMed Web of Science ®Google Scholar
• JM B, DA P, TW S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006 Dec;;12(12):1365–1371.
   PubMed Web of Science ®Google Scholar
• Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004 Sep 20;200(6):749–759.
   PubMed Web of Science ®Google Scholar
• Brenchley JM, Paiardini M, Knox KS, et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood. 2008 Oct 1;112(7):2826–2835.
   PubMed Web of Science ®Google Scholar
• Voigt RM, Keshavarzian A, Losurdo J, et al. HIV-associated mucosal gene expression: region-specific alterations. Aids. 2015 Mar 13;29(5):537–546.
   PubMed Web of Science ®Google Scholar
• Epple HJ, Allers K, Troger H, et al. Acute HIV infection induces mucosal infiltration with CD4+ and CD8+ T cells, epithelial apoptosis, and a mucosal barrier defect. Gastroenterology. 2010 Oct;139(4):1289–1300.
   PubMed Web of Science ®Google Scholar
• Suy A, Castro P, Nomdedeu M, et al. Immunological profile of heterosexual highly HIV-exposed uninfected individuals: predominant role of CD4 and CD8 T-cell activation. J Infect Dis. 2007 Oct 15;196(8):1191–1201.
   PubMed Web of Science ®Google Scholar
• Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature. 2001 Apr 26;410(6832):1099–1103.
   PubMed Web of Science ®Google Scholar
• Hearps AC, Martin GE, Angelovich TA, et al. Aging is associated with chronic innate immune activation and dysregulation of monocyte phenotype and function. Aging Cell. 2012 Oct;11(5):867–875. .
   PubMed Web of Science ®Google Scholar
• Hearps AC, Maisa A, Cheng WJ, et al. HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. Aids. 2012 Apr 24;26(7):843–853.
   PubMed Web of Science ®Google Scholar
• Nakanjako D, Ssewanyana I, Mayanja-Kizza H, et al. High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort. BMC Infect Dis. 2011 Feb 8;11(1):43.
   PubMedGoogle Scholar
• Merlini E, Tincati C, Biasin M, et al. Stimulation of PBMC and monocyte-derived macrophages via Toll-Like Receptor activates innate immune pathways in HIV-infected patients on virally suppressive combination antiretroviral therapy. Front Immunol. 2016;7:614.
   PubMed Web of Science ®Google Scholar
• Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011 Mar 15;203(6):780–790.
   PubMed Web of Science ®Google Scholar
• Massanella M, Ouchi D, Marfil S, et al. Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals. PloS One. 2014;9(12):e114142. .
   PubMed Web of Science ®Google Scholar
• Funderburg NT, Mayne E, Sieg SF, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood. 2010 Jan 14;115(2):161–167.
   PubMed Web of Science ®Google Scholar
• Marchetti G, Tincati C, Silvestri G. Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin Microbiol Rev. 2013 Jan;26(1):2–18.
   PubMed Web of Science ®Google Scholar
• Ferrando-Martinez S, De Pablo-Bernal RS, De Luna-Romero M, et al. Thymic function failure is associated with human immunodeficiency virus disease progression. Clin Infect Dis. 2017 May 1;64(9):1191–1197. .
   PubMed Web of Science ®Google Scholar
• Negredo E, Massanella M, Puig J, et al. Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications. Clin Infect Dis. 2010 May 1;50(9):1300–1308. .
   PubMed Web of Science ®Google Scholar
• Massanella M, Negredo E, Clotet B, et al. Immunodiscordant responses to HAART–mechanisms and consequences. Expert Rev Clin Immunol. 2013 Nov;9(11):1135–1149.
   PubMed Web of Science ®Google Scholar
• Massanella M, Negredo E, Perez-Alvarez N, et al. CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. Aids. 2010 Apr 24;24(7):959–968.
   PubMed Web of Science ®Google Scholar
• Pacheco YM, Jarrin I, Rosado I, et al. Increased risk of non-AIDS-related events in HIV subjects with persistent low CD4 counts despite cART in the CoRIS cohort. Antiviral Res. 2015 May;117:69–74.
   PubMed Web of Science ®Google Scholar
• Epidemiological Research in Europe (COHERE) in EuroCoord, Young J, Psichogiou M, et al. CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med. 2012; 9(3):e1001194.
   PubMed Web of Science ®Google Scholar
• Gallant J, Hsue PY, Shreay S, et al. Comorbidities among US patients with prevalent HIV infection. A Trend Analysis. The Journal of Infectious Diseases. 2017 Dec 19;216(12):1525–1533.
   PubMed Web of Science ®Google Scholar
• Christensen S, Wolf E, Altevers J, et al. Comorbidities and costs in HIV patients: A retrospective claims database analysis in Germany. PloS One. 2019;14(11):e0224279. .
   PubMed Web of Science ®Google Scholar
• Adih WK, Selik RM, Hu X. Trends in diseases reported on us death certificates that mentioned HIV infection, 1996-2006. J Int Assoc Phys AIDS Care (Chicago, Ill: 2002). 2011;10(1):5–11. . Jan-Feb
   PubMedGoogle Scholar
• Shah ASV, Stelzle D, Lee KK, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis. Circulation. 2018 Sep 11;138(11):1100–1112.
   PubMed Web of Science ®Google Scholar
• McGettrick P, Mallon PWG, Sabin CA. Cardiovascular disease in HIV patients: recent advances in predicting and managing risk. Exp Rev Anti-Infective Ther. 2020 Jul;18(7):677–688. .
   PubMed Web of Science ®Google Scholar
• Kaplan RC, Sinclair E, Landay AL, et al. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis. 2011 Feb 15;203(4):452–463.
   PubMed Web of Science ®Google Scholar
• Calza L, Pocaterra D, Pavoni M, et al. Plasma levels of VCAM-1, ICAM-1, E-Selectin, and P-Selectin in 99 HIV-positive patients versus 51 HIV-negative healthy controls. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2009 Apr 1;50(4):430–432.
   PubMed Web of Science ®Google Scholar
• Karpatkin S, Nardi M, Green D. Platelet and coagulation defects associated with HIV-1-infection. Thromb Haemost. 2002 Sep;88(9):389–401.
   PubMedGoogle Scholar
• Jacobson MC, Dezube BJ, Aboulafia DM. Thrombotic complications in patients infected with HIV in the era of highly active antiretroviral therapy: a case series. Clin Infect Dis. 2004 Oct 15;39(8):1214–1222.
   PubMed Web of Science ®Google Scholar
• Zidar DA, Juchnowski S, Ferrari B, et al. Oxidized LDL levels are increased in HIV infection and may drive monocyte activation. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2015 Jun 1;69(2):154–160.
   PubMed Web of Science ®Google Scholar
• Butt AA, Chang CC, Kuller L, et al. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med. 2011 Apr 25;171(8):737–743.
   PubMedGoogle Scholar
• Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013 Apr 22;173(8):614–622.
   PubMed Web of Science ®Google Scholar
• Wyatt CM, Winston JA, Malvestutto CD, et al. Chronic kidney disease in HIV infection: an urban epidemic. Aids. 2007 Oct 1;21(15):2101–2103.
   PubMed Web of Science ®Google Scholar
• Alfano G, Cappelli G, Fontana F, et al. Kidney Disease in HIV Infection. J Clin Med. 2019 Aug 19;8:8. .
   Web of Science ®Google Scholar
• Achhra AC, Mocroft A, Ross MJ, et al. Kidney disease in antiretroviral-naive HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT strategic timing of antiretroviral treatment (START) trial. HIV Med. 2015 Apr;16(Suppl 1):55–63. .
   PubMedGoogle Scholar
• Kalayjian RC, Lau B, Mechekano RN, et al. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. Aids. 2012 Sep 24;26(15):1907–1915.
   PubMed Web of Science ®Google Scholar
• Abraham AG, Darilay A, McKay H, et al. Kidney dysfunction and markers of inflammation in the Multicenter AIDS Cohort Study. J Infect Dis. 2015 Oct 1;212(7):1100–1110.
   PubMed Web of Science ®Google Scholar
• Chen P, Chen BK, Mosoian A, et al. Virological synapses allow HIV-1 uptake and gene expression in renal tubular epithelial cells. J Am Soc Nephrol. 2011 Mar;22(3):496–507. .
   PubMed Web of Science ®Google Scholar
• Blasi M, Balakumaran B, Chen P, et al. Renal epithelial cells produce and spread HIV-1 via T-cell contact. Aids. 2014 Oct 23;28(16):2345–2353.
   PubMed Web of Science ®Google Scholar
• Segerer S, Nelson PJ, Schlondorff D. Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol. 2000 Jan;11(1):152–176.
   PubMed Web of Science ®Google Scholar
• McGinty T, Mirmonsef P, Mallon PW, et al. Does systemic inflammation and immune activation contribute to fracture risk in HIV? Curr Opin HIV AIDS. 2016 May;11(3):253–260. .
   PubMed Web of Science ®Google Scholar
• Triant VA, Brown TT, Lee H, et al. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008 Sep;93(9):3499–3504. .
   PubMed Web of Science ®Google Scholar
• Fakruddin JM, Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem. 2003 Nov 28;278(48):48251–48258.
   PubMed Web of Science ®Google Scholar
• Ginaldi L, Di Benedetto MC, De Martinis M. Osteoporosis, inflammation and ageing. Immun Ageing. 2005 Nov;4(2):14.
   Google Scholar
• Grund B, Peng G, Gibert CL, et al. Continuous antiretroviral therapy decreases bone mineral density. Aids. 2009 Jul 31;23(12):1519–1529.
   PubMed Web of Science ®Google Scholar
• Glidden DV, Mulligan K, McMahan V, et al. Brief report: recovery of bone mineral density after discontinuation of tenofovir-based HIV pre-exposure prophylaxis. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2017 Oct 1;76(2):177–182.
   PubMed Web of Science ®Google Scholar
• Kaspar MB, Sterling RK. Mechanisms of liver disease in patients infected with HIV. BMJ Open Gastroenterol. 2017;4(1):e000166.
   PubMed Web of Science ®Google Scholar
• Marquez M, Romero-Cores P, Montes-Oca M, et al. Immune activation response in chronic HIV-infected patients: influence of Hepatitis C virus coinfection. PloS One. 2015;10(3):e0119568. .
   PubMed Web of Science ®Google Scholar
• Mastroianni CM, Lichtner M, Mascia C, et al. Molecular mechanisms of liver fibrosis in HIV/HCV coinfection. Int J Mol Sci. 2014 May 26;15(6):9184–9208.
   PubMed Web of Science ®Google Scholar
• Medrano LM, Garcia-Broncano P, Berenguer J, et al. Elevated liver stiffness is linked to increased biomarkers of inflammation and immune activation in HIV/hepatitis C virus-coinfected patients. Aids. 2018 Jun 1;32(9):1095–1105.
   PubMed Web of Science ®Google Scholar
• Patel SV, Jayaweera DT, Althoff KN, et al. Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV. PloS One. 2020;15(2):e0228847. .
   PubMed Web of Science ®Google Scholar
• Parisi SG, Andreis S, Mengoli C, et al. Soluble CD163 and soluble CD14 plasma levels but not cellular HIV-DNA decrease during successful interferon-free anti-HCV therapy in HIV-1-HCV co-infected patients on effective combined anti-HIV treatment. Med Microbiol Immunol. 2018 Aug;207(3–4):183–194. .
   PubMed Web of Science ®Google Scholar
• Leone S, Prosperi M, Costarelli S, et al. Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response. Eur J Clin Microbiol Infect Dis. 2016 Sep;35(9):1511–1520.
   PubMed Web of Science ®Google Scholar
• Cervo A, Milic J, Mazzola G, et al. Prevalence, predictors and severity of lean non-alcoholic fatty liver disease in HIV-infected patients. Clin Inf Dis. 2020 Apr;13.
   Web of Science ®Google Scholar
• Guaraldi G, Lonardo A, Maia L, et al. Metabolic concerns in aging HIV-infected persons: from serum lipid phenotype to fatty liver. Aids. 2017 Jun 1;31(Suppl 2):S147–S156.
   PubMedGoogle Scholar
• Franzetti M, Ricci E, Bonfanti P. The pattern of non-AIDS-defining cancers in the HIV population: epidemiology, risk factors and prognosis. A Review Curr HIV Res. 2019;17(1):1–12.
   PubMed Web of Science ®Google Scholar
• Mitsuyasu RT. Non-AIDS-defining cancers. Topics Anti Med. 2014;22(3):660–665. Jun-Jul
   PubMedGoogle Scholar
• Yarchoan R, Uldrick TS, Longo DL. HIV-associated cancers and related diseases. N Engl J Med. 2018 May 31;378(22):2145.
   PubMedGoogle Scholar
• Mahale P, Engels EA, Coghill AE, et al. Cancer risk in older persons living with human immunodeficiency virus infection in the United States. Clin Infect Dis. 2018 Jun 18;67(1):50–57.
   PubMed Web of Science ®Google Scholar
• Colon-Lopez V, Shiels MS, Machin M, et al. Anal cancer risk among people with HIV infection in the United States. J Clin Oncol. 2018 Jan 1;36(1):68–75.
   PubMed Web of Science ®Google Scholar
• Franzetti M, Adorni F, Parravicini C, et al. Trends and predictors of non-AIDS-defining cancers in men and women with HIV infection: a single-institution retrospective study before and after the introduction of HAART. J Acquired Immune Deficiency Syndromes. 2013 Apr 1;62(4):414–420.
   PubMed Web of Science ®Google Scholar
• Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011 May 4;103(9):753–762.
   PubMedGoogle Scholar
• Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest. 2006 May;116(5):1167–1173.
   PubMed Web of Science ®Google Scholar
• Valdez AN, Rubin LH, Neigh GN. Untangling the Gordian knot of HIV, stress, and cognitive impairment. Neurobiol Stress. 2016 Oct;4:44–54.
   PubMed Web of Science ®Google Scholar
• Ivey NS, MacLean AG, Lackner AA. Acquired immunodeficiency syndrome and the blood-brain barrier. J Neurovirol. 2009 Apr;15(2):111–122.
   PubMed Web of Science ®Google Scholar
• Sartori AC, Vance DE, Slater LZ, et al. The impact of inflammation on cognitive function in older adults: implications for healthcare practice and research. J Neurosci Nurs. 2012 Aug;44(4):206–217. .
   PubMed Web of Science ®Google Scholar
• Chen NC, Partridge AT, Sell C, et al. Fate of microglia during HIV-1 infection: from activation to senescence? Glia. 2017 Mar;65(3):431–446. .
   PubMed Web of Science ®Google Scholar
• Garvey LJ, Pavese N, Politis M, et al. Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART. Aids. 2014 Jan 2;28(1):67–72.
   PubMed Web of Science ®Google Scholar
• Carroll A, Brew B. HIV-associated neurocognitive disorders: recent advances in pathogenesis, biomarkers, and treatment. F1000Res. 2017;6:312.
   PubMedGoogle Scholar
• Neri S, Leung J, Besutti G, et al. Chronic lung disease in HIV patients. AIDS Rev. 2018;20(3):150–157. .
   PubMed Web of Science ®Google Scholar
• Lassiter C, Fan X, Joshi PC, et al. HIV-1 transgene expression in rats causes oxidant stress and alveolar epithelial barrier dysfunction. AIDS Res Ther. 2009 Feb 4;6:1. .
   PubMedGoogle Scholar
• Gundavarapu S, Mishra NC, Singh SP, et al. HIV gp120 induces mucus formation in human bronchial epithelial cells through CXCR4/alpha7-nicotinic acetylcholine receptors. PloS One. 2013;8(10):e77160. .
   PubMed Web of Science ®Google Scholar
• Beck JM, Schloss PD, Venkataraman A, et al. Multicenter comparison of lung and oral microbiomes of HIV-infected and HIV-uninfected individuals. Am J Respir Crit Care Med. 2015 Dec 1;192(11):1335–1344.
   PubMed Web of Science ®Google Scholar
• Reddy KP, Parker RA, Losina E, et al. Impact of cigarette smoking and smoking cessation on life expectancy among people with HIV: a US-based modeling study. J Infect Dis. 2016 Dec 1;214(11):1672–1681.
   PubMed Web of Science ®Google Scholar
• Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet. 2013 Mar 2;381(9868):752–762.
   PubMed Web of Science ®Google Scholar
• Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146–56. .
   PubMed Web of Science ®Google Scholar
• Schmaltz HN, Fried LP, Xue QL, et al. Chronic cytomegalovirus infection and inflammation are associated with prevalent frailty in community-dwelling older women. J Am Geriatr Soc. 2005 May;53(5):747–754. .
   PubMed Web of Science ®Google Scholar
• Blanco JR, Barrio I, Ramalle-Gomara E, et al. Gender differences for frailty in HIV-infected patients on stable antiretroviral therapy and with an undetectable viral load. PloS One. 2019;14(5):e0215764. .
   PubMed Web of Science ®Google Scholar
• Gandhi RT, McMahon DK, Bosch RJ, et al. Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation. PLoS Pathog. 2017 Apr;13(4):e1006285. .
   PubMed Web of Science ®Google Scholar
• Falasca F, Di Carlo D, De Vito C, et al. Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns. BMC Infect Dis. 2017 Aug 22;17(1):581.
   PubMed Web of Science ®Google Scholar
• Mavigner M, Delobel P, Cazabat M, et al. HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PloS One. 2009 Oct 30;4(10):e7658. .
   PubMed Web of Science ®Google Scholar
• Elvstam O, Marrone G, Medstrand P, et al. All-cause mortality and serious non-AIDS events in adults with low-level HIV viremia during combination antiretroviral therapy: results from a swedish nationwide observational study. Clin Inf Dis. 2020 Apr;9.
   Google Scholar
• Rusconi S, Vitiello P, Adorni F, et al. Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial. PloS One. 2013;8(11):e80157.
   PubMed Web of Science ®Google Scholar
• Cillo AR, Hilldorfer BB, Lalama CM, et al. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery. Aids. 2015 Oct 23;29(16):2121–2129.
   PubMed Web of Science ®Google Scholar
• Llibre JM, Buzon MJ, Massanella M, et al. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther. 2012;17(2):355–364. .
   PubMed Web of Science ®Google Scholar
• Yadav A, Kossenkov AV, Knecht VR, et al., Evidence for persistent monocyte and immune dysregulation after prolonged viral suppression despite normalization of monocyte subsets, scd14 and scd163 in HIV-infected individuals. Pathog Immun. 4(2): 324–362. 2019. .
   PubMedGoogle Scholar
• Kelesidis T, Tran TT, Stein JH, et al. Changes in inflammation and immune activation with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy: ACTG 5260s. Clin Infect Dis. 2015 Aug 15;61(4):651–660.
   PubMed Web of Science ®Google Scholar
• Castillo-Mancilla JR, Brown TT, Palella FJ Jr., et al. Partial normalization of biomarkers of inflammation and immune activation among virally suppressed men with HIV infection and high ART adherence. Open Forum Infect Dis. 2020 Apr;7(4):ofaa099. .
   PubMed Web of Science ®Google Scholar
• Boulougoura A, Sereti I. HIV infection and immune activation: the role of coinfections. Current Opinion HIV AIDS. 2016 Mar;11(2):191–200.
   PubMed Web of Science ®Google Scholar
• Lopez-Cortes LF, Trujillo-Rodriguez M, Baez-Palomo A, et al. Eradication of hepatitis C virus (HCV) reduces immune activation, microbial translocation, and the HIV DNA level in HIV/HCV-coinfected patients. J Infect Dis. 2018 Jul 13;218(4):624–632.
   PubMed Web of Science ®Google Scholar
• Hunt PW, Martin JN, Sinclair E, et al. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis. 2011 May 15;203(10):1474–1483. .
   PubMed Web of Science ®Google Scholar
• De Wit S, Delforge M, Necsoi CV, et al. Downregulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load. Aids. 2011 Jun 19;25(10):1332–1333.
   PubMed Web of Science ®Google Scholar
• Ganesan A, Crum-Cianflone N, Higgins J, et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis. 2011 Mar 15;203(6):756–764. .
   PubMed Web of Science ®Google Scholar
• Funderburg NT, Jiang Y, Debanne SM, et al. Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J Acquired Immune Deficiency Syndromes. 2015 Apr 1;68(4):396–404.
   PubMed Web of Science ®Google Scholar
• Toribio M, Fitch KV, Sanchez L, et al. Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV. Aids. 2017 Mar 27;31(6):797–806.
   PubMed Web of Science ®Google Scholar
• Nixon DE, Bosch RJ, Chan ES, et al. Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <30 mg/dl (aids clinical trials group study a5275). J Clin Lipidol. 2017 Jan - Feb;11(1):61–69.
   PubMed Web of Science ®Google Scholar
• O’Brien M, Montenont E, Hu L, et al. Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2013 Jul 1;63(3):280–288.
   PubMed Web of Science ®Google Scholar
• O’Brien MK, Kitch D, Hunt PW, et al. Aspirin fails to impact immune activation or endothelial function in treated HIV. Presented at: CROI 2016; February 22–25, 2016; Boston, Massachusetts.
   Google Scholar
• Macatangay BJC, Jackson EK, Abebe KZ, et al. A randomized.pilot clinical trial of dipyridamole to decrease HIV-associated chronic inflammation. The Journal of infectious diseases: placebo-controlled; 2019 Jul 6.
   Google Scholar
• Jacobson JM, Bosinger SE, Kang M, et al. The effect of chloroquine on immune activation and interferon signatures associated with HIV-1. AIDS Res Hum Retroviruses. 2016 Jul;32(7):636–647.
   PubMed Web of Science ®Google Scholar
• Hsue PY, Ribaudo HJ, Deeks SG, et al. Safety and impact of low-dose methotrexate on endothelial function and inflammation in individuals with treated human immunodeficiency virus: AIDS clinical trials group study A5314. Clin Infect Dis. 2019 May 17;68(11):1877–1886.
   PubMed Web of Science ®Google Scholar
• Katlama C, Lambert-Niclot S, Assoumou L, et al. Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial. Aids. 2016 Jan;30(2):221–230. .
   PubMed Web of Science ®Google Scholar
• Hsue PY, Li D, Ma Y, et al. IL-1beta inhibition reduces atherosclerotic inflammation in HIV infection. J Am Coll Cardiol. 2018 Dec 4;72(22):2809–2811.
   PubMed Web of Science ®Google Scholar
• Ruiz-Ortega M, Ruperez M, Esteban V, et al. Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant. 2006 Jan;21(1):16–20. .
   PubMed Web of Science ®Google Scholar
• Cockerham LR, Yukl SA, Harvill K, et al. A randomized controlled trial of lisinopril to decrease lymphoid fibrosis in antiretroviral-treated, HIV-infected individuals. Pathog Immun. 2017;2(3):310–334. .
   PubMedGoogle Scholar
• Baker JV, Wolfson J, Collins G, et al. Losartan to reduce inflammation and fibrosis endpoints in HIV disease (LIFE-HIV). Presented at: CROI 2020; March 8–11, 2020; Boston, MA.
   Google Scholar
• Zevin AS, McKinnon L, Burgener A, et al. Microbial translocation and microbiome dysbiosis in HIV-associated immune activation. Curr Opin HIV AIDS. 2016 Mar;11(2):182–190. .
   PubMed Web of Science ®Google Scholar
• Vazquez-Castellanos JF, Serrano-Villar S, Latorre A, et al. Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals. Mucosal Immunol. 2015 Jul;8(4):760–772. .
   PubMed Web of Science ®Google Scholar
• Dillon SM, Frank DN, Wilson CC. The gut microbiome and HIV-1 pathogenesis: a two-way street. Aids. 2016 Nov 28;30(18):2737–2751.
   PubMed Web of Science ®Google Scholar
• Roberfroid M. Prebiotics: the concept revisited. J Nutr. 2007 Mar;137(3):830S-837S. 137(3 Suppl 2):830S–7S
   PubMed Web of Science ®Google Scholar
• Sanders ME  Probiotics: definition, sources, selection, and uses. Clin Infect Dis. 2008 Feb; 1; 46 Suppl 2:S58-61; discussion S144–51.
   Google Scholar
• Gori A, Rizzardini G, Van’t Land B, et al. Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the “COPA” pilot randomized trial. Mucosal Immunol. 2011 Sep;4(5):554–563. .
   PubMed Web of Science ®Google Scholar
• Meyer-Myklestad MH, Kummen M, Stiksrud B, et al. Altered gut immunity in immunological non-responders is partly restored by probiotics. Presented at: CROI 2019; March 4–7, 2019; Seattle, Washington.
   Google Scholar
• Villar-Garcia J, Guerri-Fernandez R, Moya A, et al. Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial. PloS One. 2017;12(4):e0173802. .
   PubMed Web of Science ®Google Scholar
• Serrano-Villar S, de Lagarde M, Vazquez-Castellanos J, et al. Effects of immunonutrition in advanced human immunodeficiency virus disease: a randomized placebo-controlled clinical trial (promaltia study). Clin Infect Dis. 2019 Jan 1;68(1):120–130.
   PubMed Web of Science ®Google Scholar
• Hensley-McBain T, Zevin AS, Manuzak J, et al. Effects of fecal microbial transplantation on microbiome and immunity in simian immunodeficiency virus-infected Macaques. J Virol. 2016 May 15;90(10):4981–4989.
   PubMed Web of Science ®Google Scholar
• Wang S, Xu M, Wang W, et al. Systematic review: adverse events of fecal microbiota transplantation. PloS One. 2016;11(8):e0161174. .
   PubMed Web of Science ®Google Scholar
• Tenorio AR, Chan ES, Bosch RJ, et al. Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286. J Infect Dis. 2015 Mar 1;211(5):780–790.
   PubMed Web of Science ®Google Scholar
• Williams BB, Green SJ, Bosch RJ, et al. Four weeks of treatment with rifaximin fails to significantly alter microbial diversity in rectal samples of HIV-infected immune non-responders (actg a5286) which may be attributed to rectal swab use. Pathog Immun. 2019;4(2):235–250. .
   PubMedGoogle Scholar
• Somsouk M, Dunham RM, Cohen M, et al. The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial. PloS One. 2014;9(12):e116306. .
   PubMed Web of Science ®Google Scholar
• Kristoff J, Haret-Richter G, Ma D, et al. Early microbial translocation blockade reduces SIV-mediated inflammation and viral replication. J Clin Invest. 2014 Jun;124(6):2802–2806. .
   PubMed Web of Science ®Google Scholar
• Sandler NG, Zhang X, Bosch RJ, et al. Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. J Infect Dis. 2014 Nov 15;210(10):1549–1554.
   PubMed Web of Science ®Google Scholar
• Robinson-Papp J, Nmashie A, Pedowitz E, et al. The effect of pyridostigmine on small intestinal bacterial overgrowth (SIBO) and plasma inflammatory biomarkers in HIV-associated autonomic neuropathies. J Neurovirol. 2019 Aug;25(4):551–559. .
   PubMed Web of Science ®Google Scholar
• Bonato M, Galli L, Passeri L, et al. A pilot study of brisk walking in sedentary combination antiretroviral treatement (cART)- treated patients: benefit on soluble and cell inflammatory markers. BMC Infect Dis. 2017 Jan 11;17(1):61.
   PubMedGoogle Scholar
• Ceccarelli G, Pinacchio C, Santinelli L, et al. Physical activity and HIV: effects on fitness status, metabolism, inflammation and immune-activation. AIDS Behav. 2020 Apr;24(4):1042–1050. .
   PubMed Web of Science ®Google Scholar
• He T, Xu C, Krampe N, et al. High-fat diet exacerbates SIV pathogenesis and accelerates disease progression. J Clin Invest. 2019 Dec 2;129(12):5474–5488. .
   PubMed Web of Science ®Google Scholar
• Cioe PA, Baker J, Kojic EM, et al. Elevated soluble CD14 and lower D-Dimer are associated with cigarette smoking and heavy episodic alcohol use in persons living with HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2015 Dec 1;70(4):400–405.
   PubMed Web of Science ®Google Scholar
• Steel HC, Venter WDF, Theron AJ, et al. Effects of tobacco usage and antiretroviral therapy on biomarkers of systemic immune activation in HIV-infected participants. Mediators Inflammation. 2018;2018:8357109.
   PubMed Web of Science ®Google Scholar
• Song P, An J, Zou MH. Immune clearance of senescent cells to combat ageing and chronic diseases. Cells. 2020 Mar 10;9(3). 10.3390/cells9030671.
   Web of Science ®Google Scholar
• Szaniawski MA, Spivak AM. Senotherapeutics for HIV and aging. Current Opinion HIV AIDS. 2020 Mar;15(2):83–93.
   PubMed Web of Science ®Google Scholar